Cyclic limulus anti- lipopolysaccharide (lps) factor derived peptide shows a novel way to attenuate tnf-a production induced by lps

• In: Pharmaceutical Biotechnology Posters
• At: Lisbon (Portugal) (2010)
• Type: Poster
• Poster code: PB-P-016
• By: XIA, Peiyuan (Dept. of Pharmacy, Southwest Hospital, Third Military Medical University, Chongqing, China)
• Co-author(s): Liu, Yao (Dept. of Pharmacy, Southwest Hospital, Third Military Medical University, CHONGQING, China)
  Ren, Jiandong (Dept. of Pharmacy, Southwest Hospital, Third Military Medical University, CHONGQING, China)
  
• Abstract:

  CLP-19, a cyclic peptide derived from Limulus anti-LPS factor (LALF) which can neutralize LPS in vitro and in vivo. In this study, we show CLP-19 attenuate TNF-a production induced by LPS a novel way. Real-time PCR and ELISA analyses indicated that CLP-19 could suppress LPS-induced expression of TNF-a mRNA and protein by RAW264.7 cells. ELISA

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login